Tidiacic (thiazolidine-2,4-dicarboxylic acid) is a hepatoprotective drug that acts as an antioxidant and a sulfur donor. Tidiacic is a component of tidiacic arginine that used in France for the treatment of toxic liver damage

Volixibat (SHP626; formerly LUM002) is a potent inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that was developed for the treatment of nonalcoholic steatohepatitis. Volixibat participated in phase II clinical trial to investigate its safety, effectiveness in adults with nonalcoholic steatohepatitis. However, this study was discontinued, without any further explanation for the possible causes. In addition, volixibat was studied in a clinical trial in healthy adults and in patients with type 2 diabetes mellitus, where was shown that the drug was generally well tolerated.

Hemin (trade name Panhematin) is a protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand, which is is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women. Manifestations such as pain, hypertension, tachycardia, abnormal mental status and mild to progressive neurologic signs may be controlled in selected patients with this disorder. the therapy for the acute porphyrias is not curative. Heme acts to limit the hepatic and/or marrow synthesis of porphyrin. This action is likely due to the inhibition of δ-aminolevulinic acid synthetase, the enzyme which limits the rate of the porphyrin/heme biosynthetic pathway. The exact mechanism by which hematin produces symptomatic improvement in patients with acute episodes of the hepatic porphyrias has not been elucidated.

Magnesium isoglycyrrhizinate is a magnesium salt form of isoglycyrrhizinate, a derivative of glycyrrhizic acid extracted from the roots of the plant Glycyrrhiza glabra. Magnesium isoglycyrrhizinate has anti-inflammatory, antioxidant and hepatoprotective activities. The drug is believed to be a free radical scavenger and to modulate the activity of hepatic enzymes. Magnesium isoglycyrrhizinate was investigated in clinical trials to restore hepatic impairments caused by chemotherapy drugs and as a treatment of chronic liver diseases.